ACTA PHARMACOLOGICA SINICA-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-05-05 1851f60d27m

审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0
偏重的研究方向：药理
经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年

87 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2020-12-31 lovetcm

中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。

131 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-12-09 Small Fish 来自江苏省

偏重的研究方向：药理学;肿瘤药理学
经验分享：请问大家投稿以后多久分配编辑？

46 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-06-30 124fe17cm60(暂无昵称)

有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢

53 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-01-07 lxh

偏重的研究方向：药理学
经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？

63 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 衣谷

什么是Protocol？

61 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-12-27 ms9000000197189772 来自Dublin

偏重的研究方向：生物钟;药理学
经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？

21 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-12-14 ms9000000535156838 来自湖北省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：白血病
经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。
4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。
8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。
9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。
我的文章WB很多，但是杂志没有要求原图。

22 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-01-31 ms8000000053730142 来自江苏省

已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗

54 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=962756, encodeId=af25962e56ab, content=审稿速度:12.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：药理 经验分享：选好了期刊，碰对了审稿人，就很幸运，如果没有碰上nice的审稿人，可以给你拖一年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=66d72098763, createdName=1851f60d27m, createdTime=Wed May 05 09:15:13 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912790, encodeId=5c6d912e901a, content=中科院药物所主办的Acta Pharmaceutica Sinica B可能在2020年也要突破10分的关口。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 23:00:30 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105156, encodeId=e996210515615, content=偏重的研究方向：药理学;肿瘤药理学 经验分享：请问大家投稿以后多久分配编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34f1937121, createdName=Small Fish, createdTime=Fri Dec 09 23:08:16 CST 2022, time=2022-12-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229768, encodeId=ce0d1229e6897, content=有没有最近投的小伙伴，这个杂志现在投编辑受理，一审速度要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb322530388, createdName=124fe17cm60(暂无昵称), createdTime=Thu Jun 30 19:02:31 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181949, encodeId=0e2f1181949c1, content=偏重的研究方向：药理学 经验分享：大侠们这个杂志Awaiting EIC Decision一般要多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoJ80Ae3TNIibbjgNdXrhz5wIsCq4kqy2RgRqmMB0zM5iaTdPTOb6dwQicAJ7fOPVq6uSJwu97YN9UOg/132, createdBy=fe2a5325001, createdName=lxh, createdTime=Fri Jan 07 19:12:27 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086070, encodeId=221f10860e03b, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177630, encodeId=e32a21e7630e2, content=偏重的研究方向：生物钟;药理学 经验分享：准备投稿中，求助大家两个问题，1.APS是否需要WB未裁剪的原图？2. 是否需要上传质谱数据？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b79124773, createdName=ms9000000197189772, createdTime=Wed Dec 27 22:52:55 CST 2023, time=2023-12-27, status=1, ipAttribution=Dublin), GetPortalCommentsPageByObjectIdResponse(id=2174965, encodeId=0b0121e4965a6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：白血病 经验分享：最近刚接收了一篇，做的是白血病的联合治疗机制研究。用的药主要是中药成分。 4.17投稿，5.16收到审稿意见，拒稿重投，但是给开放了修回系统，时间给了两个月多一点。审稿意见还可以，但是要补的实验还是挺多的。当时去网上了解了一下，可能是杂志为了缩短网上的审稿时间，大修给拒稿重投的意见。这样不算审稿整体时间。 8.8修回去，9.5收到二审意见，给的大修，两个月时间，但是两个审稿人无意见了，只有第一个还有一点问题需要补实验。 9.21修回去，10.15收到三审意见，给的小修一个月，但是都是格式问题。修回去当天就收到原则性接收的邮件。 我的文章WB很多，但是杂志没有要求原图。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d0f6497044, createdName=ms9000000535156838, createdTime=Thu Dec 14 18:15:09 CST 2023, time=2023-12-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112414, encodeId=f541211241495, content=已经Awaiting Reviewer Assignment15天了，前面分配编辑和under review都很快，为什么审稿人这么难找呀，是因为这段时间过年吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06645707969, createdName=ms8000000053730142, createdTime=Tue Jan 31 17:10:01 CST 2023, time=2023-01-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1086069, encodeId=2ab110860698f, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 衣谷

什么是comment？

76 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务